Promising results for Lead Biologics’ first-in-class checkpoint inhibitor published in Nature Cancer
Lead Biologics takes a major step towards a new cancer treatment. A new study shows that the company’s drug candidate effectively inhibits a previously unknown immune escape mechanism and eliminates acute myeloid leukemia cells in advanced experimental models. – This confirms the great interest in our novel approach to treating cancer, and is an important step towards first-in-human studies, says
